Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease. Issue 11 (22nd August 2022)

• Record Type: Journal Article
• Authors: Simmering, Jacob E.; Welsh, Michael J.; Schultz, Jordan; Narayanan, Nandakumar S.
• Is Part Of: Movement disorders. Volume 37:Issue 11(2022)
• Page Start: 2210
• Page End: 2216
• Publication Date: 2022-08-22
• Subjects: Parkinson's disease -- epidemiology -- pharmacoepidemiology; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.29184
• Languages: English
• ISSNs: 0885-3185

Abstract

Abstract: Background: Terazosin (TZ) and closely related α1‐adrenergic receptor antagonists (doxazosin [DZ] and alfuzosin [AZ]) enhance glycolysis and reduce neurodegeneration in animal models. Observational evidence in humans from several databases supports this finding; however, a recent study has suggested that tamsulosin, the comparator medication, increases the risk of Parkinson's disease. Aims: We consider a different comparison group of men taking 5α‐reductase inhibitors (5ARIs) as a new, independent comparison allowing us to both obtain new estimates of the association between TZ/DZ/AZ and Parkinson's disease outcomes and validate tamsulosin as an active comparator. Methods: Using the Truven Health Analytics Marketscan database, we identified men without Parkinson's disease, newly started on TZ/DZ/AZ, tamsulosin, or 5ARIs. We followed these matched cohorts to compare the hazard of developing Parkinson's disease. We conducted sensitivity analyses using variable duration of lead‐in to mitigate biases introduced by prodromal disease. Results: We found that men taking TZ/DZ/AZ had a lower hazard of Parkinson's disease than men taking tamsulosin (hazard ratio (HR) = 0.71, 95% CI [confidence interval]: 0.65–0.77, n = 239, 888) and lower than men taking 5ARIs (HR = 0.84, 95% CI: 0.75–0.94, n = 129, 116). We found the TZ/DZ/AZ versus tamsulosin HR to be essentially unchanged with up to 5 years of lead‐in time; however, the TZ/DZ/AZ versus 5ARI effect became attenuated with longer lead‐in durations. Conclusions: These data suggest that men using TZ/DZ/AZ have a somewhat lower risk of developing Parkinson's disease than those using tamsulosin and a slightly lower risk than those using 5ARIs. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society Abstract :